DelveInsight’s “Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Peripheral Artery Disease (PAD) , historical and forecasted epidemiology as well as the Peripheral Artery Disease (PAD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Peripheral Arterial Disease Market with DelveInsight’s In-Depth Report @ Peripheral Arterial Disease Market Size

 

Key Takeaways from the Peripheral Arterial Disease Market Report

• In November 2024:- Mercator MedSystems Inc.- Temsirolimus Adventitial Delivery to Improve ANGioplasty And/or Atherectomy Revascularization Outcomes Below the Knee: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 Mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients with Symptomatic Rutherford 3-5 Peripheral Artery Disease.
• In November 2024:- CSL Behring- A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis.
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of PAD in the 7MM were nearly 18 million in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of PAD with ~2.4 million cases. On the other hand, Spain had the lowest diagnosed prevalent population (0.8 million cases).
• Japan had nearly 2 million total diagnosed prevalent cases of Peripheral artery disease PAD in 2023, accounting for approximately 10% in 7MM.
• Based on Rutherford’s criteria for severity, the highest number of PAD cases in 2023 were observed in Stage 0 i.e., 56% in the US, while Stage 6 patients were lowest (2%).
• The DelveInsight analysis indicates that among the EU4 and the UK, the PAD prevalence in females (51%) is slightly high compared to males (49%).
• The leading Peripheral Artery Disease Companies such as NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.
• Promising Peripheral Artery Disease Therapies such as Actovegin, Propionyl-L-Carnitine Hydrochloride, L-arginine 1.4% 500 ml, edoxaban, Clopidogrel, Aspirin, and others.

 

Stay ahead in the Peripheral Arterial Disease Therapeutics Market with DelveInsight’s Strategic Report @ Peripheral Arterial Disease Market Outlook

 

Peripheral Arterial Disease Epidemiology Segmentation in the 7MM

• Total Peripheral Artery Disease Diagnosed Prevalent Cases
• Peripheral Artery Disease Gender-specific Diagnosed Prevalent Cases
• Peripheral Artery Disease Age-specific Diagnosed Prevalent Cases
• Peripheral Artery Disease Severity-specific Diagnosed Prevalent Cases

 

Download the report to understand which factors are driving Peripheral Arterial Disease epidemiology trends @ Peripheral Arterial Disease Prevalence

 

Peripheral Artery Disease Marketed Drugs

• XARELTO (rivaroxaban): Bayer/ Johnson & Johnson

XARELTO is an oral anticoagulant for the treatment and prevention of blood clots. In combination with aspirin, it is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO can cause bleeding, which can be serious and may lead to death, as it is a blood thinner medicine (anticoagulant) that lowers blood clotting. In June 2022, the Ministry of Health, Labour and Welfare in Japan approved XARELTO (2.5 mg twice daily, used in combination with aspirin 81–100 mg once daily) to treat patients with PAD after revascularization.

 

• ZONTIVITY (Vorapaxar): Xspire Pharma/ Aralez Pharmaceuticals/ Merck

ZONTIVITY is indicated for reducing thrombotic cardiovascular events in patients with a history of MI or with PAD. ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and UCR. In May 2014, Merck received US FDA approval for ZONTIVITY to treat patients with PAD

 

Emerging Peripheral Artery Disease Drugs

• Honedra (LSTA12): Lisata Therapeutics

Critical limb ischemia (CLI) is a severe obstruction of the arteries which markedly reduces blood flow to the extremities (hands, feet, and legs). CLI is the advanced form of peripheral arterial disease (PAD) caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque. LSTA12 (also known as Honedra and CLBS12 in Japan) is an experimental regenerative medicine to prevent the serious adverse consequences of CLI and Buerger’s disease by improving blood flow in the affected limb. It is CD34+ cell therapy intended to administer by Intramuscular route, 20 injections in the target limb in a single treatment.

 

• ACP-01: Hemostemix Inc..

ACP-01, Hemostemix’s lead clinical candidate, is an autologous cell therapy to treat critical limb ischemia (CLI) in patients facing amputation. ACP-01 consists of cells derived from the patient’s blood and modified with Hemostemix’s technology that forms new blood vessels. These cells, known as angiogenic cell precursors, or ACPs, secrete growth factors and cytokines that support the formation of blood vessels through vasculogenesis and angiogenesis. Factors secreted by ACPs also facilitate the recruitment of additional progenitor cells to promote the healing of damaged tissues. When these cells are injected into the dying leg muscle of the same patient with critical limb ischemia, they support the regeneration of new small blood vessels and may prevent amputations.

 

Get In-Depth Knowledge on Peripheral Arterial Disease Market Trends and Forecasts with DelveInsight @ Peripheral Arterial Disease Treatment Market

 

Peripheral Artery Disease Market Outlook

Peripheral Artery Disease (PAD) presents various limb-related complications, including intermittent claudication, ischemic rest pain, ulcers, gangrene, and functional impairment. Comprehensive medical treatment involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise, and smoking cessation. Treatment options include lifestyle changes, medication, endovascular and surgical interventions, and emerging therapies like gene and cell therapy. Despite available treatments, PAD is often undertreated compared to coronary artery disease.

 

Peripheral Arterial Disease Treatment Market

Critical Limb Ischemia (CLI) treatment aims to relieve pain, restore blood flow, and preserve limb function. Strategies include endovascular and surgical revascularization, with therapeutic angiogenesis using gene and cell therapies showing promise. The goals for CLI management are pain relief, healing of lesions, prevention of amputations, and improvement of quality of life and survival. An interdisciplinary approach is essential, with monitoring and managing cardiovascular risk factors being crucial for all PAD patients.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Peripheral Arterial Disease Market Report @ Peripheral Arterial Disease Market Drivers and Barriers

 

Scope of the Peripheral Arterial Disease Market Report

• Coverage- 7MM
• Peripheral Arterial Disease Companies- NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.
• Peripheral Artery Disease Therapies- Actovegin, Propionyl-L-Carnitine Hydrochloride, L-arginine 1.4% 500 ml, edoxaban, Clopidogrel, Aspirin, and others.
• Peripheral Arterial Disease Therapeutic Assessment: Peripheral Arterial Disease Current marketed and Influenza A Infections emerging therapies
• Peripheral Arterial Disease Market Dynamics: Peripheral Arterial Disease Market Drivers and Peripheral Arterial Disease Market Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Peripheral Artery Disease (PAD) Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Executive Summary of Peripheral Artery Disease (PAD)

6 Key Events

7 Disease Background and Overview: Peripheral Artery Disease (PAD)

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 Peripheral Artery Disease (PAD) : Seven Major Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity